Early clinical experience with the new Amplatzer Ductal Occluder II for closure of the persistent arterial duct

Abstract

Objective: To describe early single-centre clinical experience with the Amplatzer Ductal Occluder II (ADO II).Method: Children with a haemodynamically significant patent ductus arteriosus (PDA) who underwent percutaneous trans-pulmonary closure with Amplatzer Ductal Occluder II (ADO2) were included. Data was collected from computer based patient records.Results: Trans-pulmonary PDA closures using ADO 2 were undertaken in 32 children (22 females) with a mean age of 1year 9 months (range 5 months to 10 years) and a mean weight of 8.2kg (range 4.2-25kg). Complete occlusion was noted pre-discharge in 31 (97%) patients. One (3%) had residual shunting after deployment followed by embolization to the left pulmonary artery on the third day of the procedure. One (3%) had mild flow acceleration in the left pulmonary artery and another (3%) had mild aortic flow obstruction following the procedure. At 7 and 30 days, echocardiography confirmed complete ductal occlusion without need for further intervention in all 31 (97%) successful cases.Conclusion: ADO II is highly effective in rapid occlusion of morphologically varied small to moderate-sized PDAs.